Linda Casey, RN, shares essential strategies for oncology nurses to protect vulnerable patients from the clinical risks of wildfire smoke exposure. As Canadian wildfire smoke blanketed the tri-state ...

Chasity Washington MPH, CHES | Authors | Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

The FDA has granted traditional approval to selpercatinib for adult and pediatric patients with RET fusion-positive solid tumors post-progression. The Food and Drug Administration (FDA) has converted ...

The Food and Drug Administration (FDA) has approved gedatolisib (Revtorpyk) for use in combination with fulvestrant, with or without palbociclib. This approval specifically targets adult patients with ...

FDA expanded pembrolizumab and enfortumab vedotin-ejfv for all surgery-eligible adults with muscle-invasive bladder cancer following positive trial data. The Food and Drug Administration (FDA) has ...

The WHO 2026 report warns of a global cancer surge by 2050, highlighting critical inequities and the need for people-centered oncology nursing care. The global oncology landscape is facing an ...

FDA approves subcutaneous isatuximab-irfc for multiple myeloma indications, offering an efficient delivery alternative to intravenous administration. The US Food and Drug Administration (FDA) has ...

A real-world study presented at ESMO GI shows fruquintinib is effective in mCRC, with the best outcomes in the third-line setting. Findings from a retrospective, real-world analysis presented at the ...

Long-term data show watch-and-wait is viable for rectal cancer, with most regrowths salvageable despite adverse baseline MRI features. Long-term data presented at the ESMO GI 2026 Congress provide new ...

PADCEV (enfortumab vedotin-ejfv) can cause severe and fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which occurred predominantly ...

FDA approves gedatolisib for HR+/HER2- breast cancer. Learn about the VIKTORIA-1 trial, dosing, and nursing strategies for managing stomatitis. The FDA has granted traditional approval to ...